Roche (OTCMKTS:RHHBY) Rating Increased to Strong-Buy at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Roche (OTCMKTS:RHHBY) to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

Roche Stock Down 1.5 %

Shares of RHHBY opened at $39.25 on Thursday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26. The company’s 50-day moving average price is $36.14 and its 200 day moving average price is $38.25. Roche has a 12-month low of $29.20 and a 12-month high of $42.43.

Institutional Trading of Roche

A number of institutional investors and hedge funds have recently bought and sold shares of RHHBY. Hantz Financial Services Inc. boosted its holdings in Roche by 0.9% in the fourth quarter. Hantz Financial Services Inc. now owns 33,708 shares of the company’s stock valued at $1,176,000 after purchasing an additional 305 shares in the last quarter. Canopy Partners LLC boosted its holdings in shares of Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock valued at $310,000 after acquiring an additional 344 shares during the period. Brooklyn Investment Group raised its stake in shares of Roche by 36.6% during the fourth quarter. Brooklyn Investment Group now owns 1,354 shares of the company’s stock worth $48,000 after purchasing an additional 363 shares during the last quarter. Diversified Trust Co raised its stake in shares of Roche by 1.2% during the fourth quarter. Diversified Trust Co now owns 60,453 shares of the company’s stock worth $2,130,000 after purchasing an additional 711 shares during the last quarter. Finally, Verity Asset Management Inc. raised its stake in shares of Roche by 26.8% during the fourth quarter. Verity Asset Management Inc. now owns 8,036 shares of the company’s stock worth $280,000 after purchasing an additional 1,697 shares during the last quarter.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.